FOR IMMEDIATE RELEASE:
PrimeraDx Appoints Ted Myles as Chief Financial Officer
Mansfield, MA — December 1, 2008 — PrimeraDx today announced that on November 19, 2008, Ted Myles joined the company as Chief Financial Officer.
“We are delighted to welcome Ted to PrimeraDx,” said Martin L. Verhoef, President and CEO of PrimeraDx. He brings a wide range of financial, accounting and strategic expertise and his appointment strengthens the Company as we continue to advance our products to market.”
"I am pleased to be working with PrimeraDx,” said Mr Myles. “The Company is well positioned to play a prominent role in the field of Molecular Diagnostics. PrimeraDx’s proprietary STAR technology will address a fast growing need for multiplexed and quantitative analysis in both infectious disease and oncology patient management."
Mr. Myles most recently served as the Senior Vice President of Finance & CFO of Pressure BioSciences, a Nasdaq-listed life science company. Prior to Pressure BioSciences, Mr. Myles was the Controller for EMD Pharmaceuticals, a wholly-owned affiliate of Merck KgaA, where he held a variety of responsibilities ranging from accounting to licensing and business development. Previously, Mr. Myles worked at SG Cowen Securities Corporation in the Health Care Investment Banking Group. He began his career with PriceWaterhouseCoopers, where he held positions of increasing responsibility providing business assurance services to various public and private middle market clients. Mr. Myles holds a B.S.B.A. in Accounting and Economics/Finance from the University of Hartford, an MBA from Washington University in St. Louis and is a CPA in Massachusetts.
PrimeraDx is dedicated to the emerging field of molecular diagnostics. The Company is developing multiplexed, quantitative and cost effective assays using its proprietary STAR technology implemented on the ICEPlex instrument platform. STAR combines quantitative PCR with the ability to multiplex up to 60 targets in a single sample. The Company’s initial products will be for infectious disease management. PrimeraDx plans to extend its focus into oncology to support cancer therapy management through diagnostic, prognostic, staging and therapeutic monitoring.